会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • CO-CRYSTALLINE FORMS OF CARBAMAZEPINE
    • 碳水化合物的结晶形式
    • WO2008108639A1
    • 2008-09-12
    • PCT/NL2008/000076
    • 2008-03-07
    • AVANTIUM HOLDING B.V.RAS, Erik-Jan
    • RAS, Erik-Jan
    • C07D223/26A61K31/55A61P25/08
    • C07D223/26
    • The present invention provides a novel crystalline form of a cocrystal of carbamazepine : glycolamide and of a co-crystal of carbamazepine : lactamide. The invention further provides methods for the preparation of a co-crystal of carbamazepine: glycolamide and and/or carbamazepine : lactamide, as well as their use in pharmaceutical applications, in particular in medicaments for he treatment of epilepsy, bipolar disorder, schizophrenia and/or trigeminal neuralgia. The co-crystalline form of carbamazepine: glycolamide and/ or carbamazepine : lactamide can be used in combination with other medicaments.
    • 本发明提供了一种新型的卡马西平:乙二醇酰胺和卡马西平:乳酰胺共结晶的结晶形式。 本发明还提供了用于制备卡马西平:乙二醇酰胺和/或卡马西平:乳酰胺的共晶体的方法,以及它们在药物应用中的用途,特别是用于治疗癫痫,双相性精神障碍,精神分裂症和/ 或三叉神经痛。 卡马西平:乙二醇酰胺和/或卡马西平:乳酰胺的共晶形式可以与其他药物组合使用。
    • 4. 发明申请
    • METHOD FOR THE PREPARATION OF A CO-CRYSTAL
    • 制备共晶的方法
    • WO2008035960A2
    • 2008-03-27
    • PCT/NL2007000226
    • 2007-09-13
    • AVANTIUM INT BVMCKAY BENJAMINRAS ERIK-JANMAZUREK JAROSLAW MAREKCAINS PETER
    • MCKAY BENJAMINRAS ERIK-JANMAZUREK JAROSLAW MAREKCAINS PETER
    • G06F19/00G06F19/16
    • G06F19/704G06F19/701
    • Method for the preparation of a co-crystal from an Active Pharmaceutical Ingredient (API) and a co-moiety by providing a molecular model representing at least a part of the physical and chemical properties of the API; providing a molecular model for each of a set of known co-moieties representing at least a part of the physical and chemical properties of each respective co-moiety; for each co-moiety in the set of step (b), determining whether at least one hydrogen-bond between the ACI molecule and the co-moiety is possible by comparing the molecular model of the ACI molecule as provided in step (a) and the molecular model of the co-moiety as provided in step (b); and excluding any co-moiety not capable of hydrogen-bonding with the ACI molecule, thereby obtaining a set of hydrogen-bonding co-moieties, selecting a suitable solvent and performing a set of experiments providing co-crystals of the API.
    • 通过提供代表API的物理和化学性质的至少一部分的分子模型,由活性药物成分(API)和共同部分制备共晶的方法; 为表示每个相应共部分的物理和化学性质的至少一部分的一组已知共部分中的每一个提供分子模型; 对于步骤(b)的组中的每个共部分,通过比较步骤(a)和步骤(a)中提供的ACI分子的分子模型,确定ACI分子和共部分之间的至少一个氢键是否可能 步骤(b)中提供的共部分的分子模型; 并排除任何不能与ACI分子氢键结合的共部分,从而获得一组氢键部分,选择合适的溶剂并进行一系列提供API共晶的实验。